Tenpoint Therapeutics is seeking to expand availability of its once-daily presbyopia eye drop beyond the United States, announcing a submission to apply for regulatory approval in the United Kingdom.
Yuvezzi received approval from the US Food and Drug Administration (FDA) in January this year as the first and only dual-agent (combination) eye drop approved for the treatment of presbyopia in adults.
Tenpoint Therapeutics’ CEO Henric Bjarke said the submission to the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA), for the review and approval of carbachol and brimonidine tartrate ophthalmic solution 2.75%/0.1%, was a “meaningful step in our commitment to bringing Yuvezzi to patients beyond the [United States]”.
“Blurry close-up vision is among the most prevalent age-related conditions… affecting a significant proportion of adults over the age of 45, yet currently there are no prescription eye drops approved to help people with their presbyopia,” Mr Bjarke said in a media release.1
Tenpoint Therapeutics is also working to submit regulatory applications for Yuvezzi in key regions around the world.
Blurry close-up vision is among the most prevalent age-related conditions… yet currently there are no prescription eye drops approved to help people with their presbyopia
Reference
- Tenpoint Therapeutics, Tenpoint Therapeutics announces United Kingdom YUVEZZI submission of marketing authorization application to the Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of blurry close-up vision (presbyopia) in adults, news release, 13 July 2026. Available at: businesswire.com/news/home/20260713403162/en [accessed July 2026].
